» Articles » PMID: 34244013

Associations of Retention on Buprenorphine for Opioid Use Disorder with Patient Characteristics and Models of Care in the Primary Care Setting

Overview
Specialty Psychiatry
Date 2021 Jul 10
PMID 34244013
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Buprenorphine, a medication for opioid use disorder (OUD), can be administered within primary care; however, little is known about characteristics associated with retention on buprenorphine in these settings. This study examines patient correlates of buprenorphine retention and whether an integrated, interdisciplinary treatment model (buprenorphine and behavioral health) is associated with higher odds of buprenorphine retention than a primarily medication-only treatment model.

Methods: Electronic health record data from adult patients with an OUD, ≥1 buprenorphine order and ≥1 visit to either of two primary care clinics between 9/2/2014-6/27/2018 were extracted (N = 494 patients). Two research team members reviewed the medication start and stop dates for each buprenorphine order and classified as retained (≥6 months of orders) or not retained (<6 months of orders). Logistic regressions estimated the odds of retention on buprenorphine by 1) patient characteristics and 2) timing of patient's engagement in buprenorphine treatment (pre- or post-implementation of an integrated treatment model).

Results: Of the study sample, 53% had ≥6 months of buprenorphine orders. Almost two times higher odds of retention were found among patients with ≥1 psychiatric comorbidity (versus none) and among those with buprenorphine orders in the post- versus pre-period.

Conclusions: An integrated, interdisciplinary model of OUD treatment was associated with ≥6 months of buprenorphine orders among our study population. Continued research is needed in real-world primary care settings to understand the impact of OUD treatment models on patient outcomes. A more nuanced examination of the associations between psychiatric diagnoses and buprenorphine treatment retention is warranted.

Citing Articles

Organization of primary care and early MOUD discontinuation.

Harris R, Kearney M, Keddem S, Calderbank T, Tomczuk L, Clapp J Addict Sci Clin Pract. 2024; 19(1):96.

PMID: 39702538 PMC: 11658460. DOI: 10.1186/s13722-024-00527-w.


Pain, Substance Use Disorders, Mental Health, and Buprenorphine Treatment among Patients With and Without HIV.

Miller E, McGinnis K, Edelman E, Feinberg T, Gordon K, Kerns R AIDS Behav. 2024; 28(12):3994-4004.

PMID: 39264485 PMC: 11586311. DOI: 10.1007/s10461-024-04494-w.


"They Ask Questions, But They Don't Want the Answers"-Perceptions of Clinical Communication Among Veterans Discontinuing Buprenorphine for the Treatment of Opioid Use Disorder.

Eckhardt A, Waller D, Shull S, Lovejoy T, Morasco B, Gordon A Subst Use Addctn J. 2024; 45(4):674-681.

PMID: 38767274 PMC: 11458360. DOI: 10.1177/29767342241251761.


Composition of buprenorphine prescribing networks in Medicaid and association with quality of care.

Zhu J, Charlesworth C, Stein B, Drake C, Polsky D, Korthuis P J Subst Use Addict Treat. 2024; 163:209363.

PMID: 38641055 PMC: 11203204. DOI: 10.1016/j.josat.2024.209363.


Barriers to retention in medications for opioid use disorder treatment in real-world practice.

Villamil V, Underwood N, Cremer L, Rooks-Peck C, Jiang X, Guy G J Subst Use Addict Treat. 2024; 160:209310.

PMID: 38331319 PMC: 11060890. DOI: 10.1016/j.josat.2024.209310.


References
1.
Ghabrash M, Bahremand A, Veilleux M, Blais-Normandin G, Chicoine G, Sutra-Cole C . Depression and Outcomes of Methadone and Buprenorphine Treatment Among People with Opioid Use Disorders: A Literature Review. J Dual Diagn. 2020; 16(2):191-207. DOI: 10.1080/15504263.2020.1726549. View

2.
Wakeman S, Larochelle M, Ameli O, Chaisson C, McPheeters J, Crown W . Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. JAMA Netw Open. 2020; 3(2):e1920622. PMC: 11143463. DOI: 10.1001/jamanetworkopen.2019.20622. View

3.
Manhapra A, Agbese E, Leslie D, Rosenheck R . Three-Year Retention in Buprenorphine Treatment for Opioid Use Disorder Among Privately Insured Adults. Psychiatr Serv. 2018; 69(7):768-776. DOI: 10.1176/appi.ps.201700363. View

4.
Hooker S, Sherman M, Lonergan-Cullum M, Sattler A, Liese B, Justesen K . Mental Health and Psychosocial Needs of Patients Being Treated for Opioid Use Disorder in a Primary Care Residency Clinic. J Prim Care Community Health. 2020; 11:2150132720932017. PMC: 7278330. DOI: 10.1177/2150132720932017. View

5.
Williams A, Nunes E, Bisaga A, Levin F, Olfson M . Development of a Cascade of Care for responding to the opioid epidemic. Am J Drug Alcohol Abuse. 2019; 45(1):1-10. PMC: 6404749. DOI: 10.1080/00952990.2018.1546862. View